A detailed history of U.S. Capital Wealth Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, U.S. Capital Wealth Advisors, LLC holds 2,232 shares of VRTX stock, worth $1.04 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,232
Previous 2,369 5.78%
Holding current value
$1.04 Million
Previous $990,000 5.66%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 11, 2024

SELL
$392.81 - $485.53 $53,814 - $66,517
-137 Reduced 5.78%
2,232 $1.05 Million
Q1 2024

May 10, 2024

BUY
$407.69 - $446.08 $344,498 - $376,937
845 Added 55.45%
2,369 $990,000
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $235,984 - $282,547
688 Added 82.3%
1,524 $620,000
Q3 2023

Oct 19, 2023

SELL
$338.18 - $362.46 $4.46 Million - $4.78 Million
-13,184 Reduced 94.04%
836 $290,000
Q2 2023

Aug 04, 2023

SELL
$314.42 - $351.91 $112,562 - $125,983
-358 Reduced 2.49%
14,020 $4.93 Million
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $71,373 - $81,421
-252 Reduced 1.72%
14,378 $4.53 Million
Q4 2022

Feb 03, 2023

SELL
$285.76 - $321.48 $160,882 - $180,993
-563 Reduced 3.71%
14,630 $4.22 Million
Q3 2022

Nov 01, 2022

SELL
$273.83 - $305.53 $149,237 - $166,513
-545 Reduced 3.46%
15,193 $4.4 Million
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $157,188 - $195,715
-669 Reduced 4.08%
15,738 $4.44 Million
Q1 2022

May 12, 2022

SELL
$221.42 - $260.97 $155,658 - $183,461
-703 Reduced 4.11%
16,407 $4.28 Million
Q4 2021

Jan 21, 2022

SELL
$177.01 - $223.45 $87,442 - $110,384
-494 Reduced 2.81%
17,110 $3.76 Million
Q3 2021

Nov 01, 2021

BUY
$181.39 - $202.99 $3.19 Million - $3.57 Million
17,604 New
17,604 $3.19 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track U.S. Capital Wealth Advisors, LLC Portfolio

Follow U.S. Capital Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of U.S. Capital Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on U.S. Capital Wealth Advisors, LLC with notifications on news.